Cited 4 times in
Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김영태 | - |
dc.date.accessioned | 2014-12-18T09:07:24Z | - |
dc.date.available | 2014-12-18T09:07:24Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87577 | - |
dc.description.abstract | OBJECTIVE: We performed a cost-utility analysis to assess the cost-effectiveness of a chemotherapy sequence including a combination of polyethylene glycolated liposomal doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in women with platinum-sensitive ovarian cancer. METHODS: A Markov model was constructed with a 10-year time horizon. The treatment sequence consisted of first- to sixth-line chemotherapies and best supportive care (BSC) before death. Cycle length, a time interval for efficacy evaluation of chemotherapy, was 9 weeks. The model consisted of four health states: responsive, progressive, clinical remission, and death. At any given time, a patient may have remained on a current therapy or made a transition to the next therapy or death. Median time to progressions and overall survivals data were obtained through a systematic literature review and were pooled using a meta-analytical approach. If unavailable, this was elicited from an expert panel (eg, BSC). These outcomes were converted to transition probabilities using an appropriate formula. Direct costs included drug-acquisition costs for chemotherapies, premedication, adverse-event treatment and monitoring, efficacy evaluation, BSC, drug administration, and follow-up tests during remission. Indirect costs were transportation expenses. Utilities were also derived from the literature. Costs and utilities were discounted at an annual rate of 5% per cycle. RESULTS: PLD/carboplatin combination as the second line in the sequence is more effective and costly than paclitaxel/carboplatin combination, showing an additional US$21,658 per quality-adjusted life years. This result was robust in a deterministic sensitivity analysis except when median time to progression of second-line therapies and administration cost of PLD/carboplatin per administration cycle were varied. The probability of cost-effectiveness for PLD/carboplatin combination was 49.4% at a willingness to pay $20,000. CONCLUSION: A PLD/carboplatin combination is an economically valuable option as second-line chemotherapy for the treatment of platinum-sensitive ovarian cancer in South Korea. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isPartOf | CLINICOECONOMICS AND OUTCOMES RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Hwa-Young Lee | - |
dc.contributor.googleauthor | Bong-Min Yang | - |
dc.contributor.googleauthor | Ji-Min Hong | - |
dc.contributor.googleauthor | Tae-Jin Lee | - |
dc.contributor.googleauthor | Byoung-Gie Kim | - |
dc.contributor.googleauthor | Jae-Weon Kim | - |
dc.contributor.googleauthor | Young-Tae Kim | - |
dc.contributor.googleauthor | Yong-Man Kim | - |
dc.contributor.googleauthor | Sokbom Kang | - |
dc.identifier.doi | 10.2147/CEOR.S42170 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00729 | - |
dc.relation.journalcode | J00617 | - |
dc.identifier.eissn | 1178-6981 | - |
dc.identifier.pmid | 23869171 | - |
dc.subject.keyword | Markov modeling | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | cost | - |
dc.subject.keyword | ovarian cancer | - |
dc.subject.keyword | utility | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 5 | - |
dc.citation.startPage | 297 | - |
dc.citation.endPage | 307 | - |
dc.identifier.bibliographicCitation | CLINICOECONOMICS AND OUTCOMES RESEARCH , Vol.5 : 297-307, 2013 | - |
dc.identifier.rimsid | 34323 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.